DiaSorin’s LIAISON® SARS-CoV-2 Diagnostic Solutions

The testing solutions for the detection of SARS-CoV-2

DiaSorin strives to improve health-care around the globe through the development of innovative diagnostic solutions that can lead to better patient outcomes and provide economic benefits to the healthcare system. Thanks to its team of dedicated scientists DiaSorin has been able to promptly deliver diagnostic solutions to manage the COVID-19 pandemic emergency.

DiaSorin provides diagnostic laboratories with solutions that include detection of SARS-CoV-2 Ag, antibodies determination and molecular testing:

  • LIAISON® SARS-CoV-2 Ag
  • LIAISON® SARS-CoV-2 IgM
  • LIAISON® SARS-CoV-2 TrimericS IgG (New!)
  • LIAISON® SARS-CoV-2 S1/S2 IgG

Simplexa™ COVID-19 Direct Kit  - For more info visit DiaSorin Molecular


A high-quality tool to verify immune responses of vaccinated individuals

DiaSorin is supporting Public Health Systems confirm the efficacy of their vaccination strategy with a cost-effective, automated, high-throughput SARS-CoV-2 serology testing solution.

  • The LIAISON® SARS-CoV-2 TrimericS IgG assay enables the reliable detection of Trimeric S spike protein IgG antibodies – the body’s natural defense response against SARS-CoV-2.
  • The LIAISON® SARS-CoV-2 TrimericS IgG assay is able to identify patients diagnosed for COVID-19 by virus variants (Lineage B.1.1.7 and Lineage P.1)
  • The solution was used to evaluate pre- and post-vaccination samples to support the Italian national vaccine program at a hospital in Alessandria (Italy)
  • A total of 102 sets of samples were collected from apparently healthy adults that were SARS-CoV-2 IgG negative at the time of vaccine and who received the full course (2 injections) of the Pfizer vaccine, COMIRNATY® 
  • The LIAISON® SARS-CoV-2 TrimericS IgG was able to verify the effectiveness of the vaccine with a sensitivity of 99% (21 days after the first injection) and 100% (21 days after the second injection).

    READ MORE

A quantitative assay for immune status monitoring with an accurate correlation of neutralizing IgG antibodies

The LIAISON® SARS-CoV-2 TrimericS IgG assay is the second generation of DiaSorin serological tests with an important diagnostics improvement. The selection of a new recombinant Trimeric Spike glycoprotein as a capture antigen, offers a new product with high standard quality that provides the following benefits:

  • A quantitative assay for the detection of IgG antibodies anti-Trimeric Spike glycoprotein of SARS-CoV-2
  • Trimeric Spike Glycoprotein is the stabilized native form of the SARS-CoV-2 Spike protein and a stabilized trimer may elicit an accurate detection of IgG Neutralizing antibodies
  • Clinical Sensitivity: 98.7% - Clinical Specificity: 99.5%
  • Correlation with Microneutralization test: PPA: 100%, NPA: 96.9%
  • A fully automated solution with up to 171 results/hour on LIAISON® XL
  • Complete traceability combined with a simplified sample workflow

The Selection of the antigen for the assay: the value of using SARS-CoV-2 recombinant Trimeric S Glycoprotein.

  • Trimeric Spike Glycoprotein is a stabilized trimer offering an improved detection of IgG Neutralizing antibodies.
  • For diagnostics, the Trimeric Spike Glycoprotein detects a broader repertoire of Neutralizing Antibodies improving sensitivity and accuracy of the immune status monitoring.
  • Trimeric Spike Glycoprotein improved the sensitivity and the specificity with a better correlation with the Microneutralization test.




 Download the IgG and IgM FAQs 

LIAISON® SARS-CoV-2 Ag
A quantitative Antigen assay to achieve maximum impact in testing COVID-19 patients

 

 

 

  • A quantitative assay for the detection of Nucleocapsid protein of SARS-CoV-2
  • A fully automated solution with up to 136 results/hour on LIAISON® XL
  • Clinical Sensitivity on NS sample is 97.1% (95% CI: 85.5 – 99.5%) on samples positive for Real time PCR within 10 days from onset symptoms
  • Clinical Specificity on NS sample is 100% (95% CI: 96.5 – 100%)
LIAISON® SARS-CoV-2 IgM
A new qualitative assay for the detection of IgM antibodies to SARS-CoV-2

 

 

 

  • A qualitative assay for the detection of IgM antibodies against S1-RBD antigens of SARS-CoV-2
  • A fully automated solution on LIAISON® XL
  • High sensitivity and specificity to ensure accurate results
LIAISON® SARS-CoV-2 TrimericS IgG assay

A quantitative assay for immune status monitoring with an accurate correlation of neutralizing IgG antibodies

LIAISON® SARS-CoV-2 S1/S2 IgG
A quantitative assay with correlation to neutralizing antibodies

 

 

 

  • A quantitative assay for the detection of IgG antibodies against S1/S2 antigens of SARS-CoV-2
  • A fully automated solution with up to 170 results/hour on LIAISON® XL
  • Detection of Neutralizing antibodies: 94.4% positive agreement to Plaque Reduction Neutralization Test (PRNT90)
  • High sensitivity and specificity to assure accurate results
Combined IgG and IgM testing
The combined testing solutions for the detection of antibodies to SARS-CoV-2

 

 

 

  • Combined detection of IgM and IgG can be used to assess the immune status of patients exposed to and infected by SARS-CoV-2.
  • The use of IgG and IgM in combination can aid to shorten the diagnostic window improving the detection of seroconversion up to day 15 from PCR positivity